A Randomized, Subject and Investigator-blinded, Placebo Controlled, Cross-over, Multi-center Proof of Concept (PoC) Study to Assess the Wakefulness Promoting Effect, Safety, Tolerability, and PK of LML134 in Shift Work Disorder (SWD) Patients
Phase of Trial: Phase II
Latest Information Update: 10 Oct 2018
At a glance
- Drugs LML 134 (Primary)
- Indications Circadian rhythm sleep disorders
- Focus Proof of concept; Therapeutic Use
- Sponsors Novartis Pharmaceuticals
- 01 Oct 2018 Status changed from recruiting to completed.
- 21 Aug 2018 Planned End Date changed from 21 Nov 2019 to 27 Sep 2018.
- 21 Aug 2018 Planned primary completion date changed from 21 Nov 2019 to 27 Sep 2018.